References
REFERENCES
1. Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study. Neurology. 2015;85(12):1048-1055. doi:10.1212/WNL.0000000000001950. 2. Marden JR, Freimark J, Yao Z, Signorovitch J, Tian C, Wong BL. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. J Comp Eff Res. 2020;9(3):177-189. doi:10.2217/cer-2019-0170. 3. Emflaza. Package insert. PTC Therapeutics, Inc; 2020.4. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management [published correction appears in Lancet Neurol. 2018 Apr 4]. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3. 5. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93. doi:10.1016/S1474-4422(09)70271-6. 6. Parente L. Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids. BMC Pharmacol Toxicol. 2017;18(1):1. Published 2017 Jan 5. doi:10.1186/s40360-016-0111-8. 7. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131. doi:10.1212/WNL.0000000000003217.
8. Weber DR, Hadjiyannakis S, McMillan HJ, Noritz G, Ward LM. Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy. Pediatrics. 2018;142(Suppl 2):S43-S52. doi:10.1542/peds.2018-0333F. 9. Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord. 2011;21(4):298-303. doi:10.1016/j.nmd.2011.02.006. 10. McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451-461. doi:10.1016/S0140-6736(17)32160-8. 11. Supplement to: McDonald CM, Henricson EK, Abresch RT, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2017; published online Nov 22. http://dx.doi.org/10.1016/S0140-6736(17)32160-8. 12. FDA approves deflazacort for Duchenne muscular dystrophy but manufacturer delays launch over price concerns. The Pharmaceutical Journal. 2017. doi:10.1211/pj.2017.20202344. 13. Imperatives For Duchenne MD. Parent Project Muscular Dystrophy. https://www.parentprojectmd.org/wp content/uploads/2018/04/ImperativesForDuchenneMD.pdf. Accessed March 24, 2021. 14. McDonald CM, Henricson EK, Abresch RT, et al. The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve. 2013;48(1):32-54. doi:10.1002/mus.23807. 15. Moxley RT 3rd, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2005;64(1):13-20. doi:10.1212/01.WNL.0000148485.00049.B7.